Komori
Eisai (4523) · InitiativeFirst stated

Discontinuation of BELVIQ's development for obesity in Japan

First written in FY2019. . Latest entry: FY2019.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Discontinuation of BELVIQ Development for Obesity in JapanA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2019First statedAnnual report

    「当連結会計年度において、肥満症治療剤lorcaserin（一般名、米国製品名：「BELVIQ」）の日本での肥満症を対象とした開発を中断しました。」

    BELVIQの日本における肥満症向け開発を中断し、関連するIPR&D資産について25億27百万円の減損損失を研究開発費に計上した。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Eisai yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.